- Home
- WRN vs ACIU Comparison
WRN vs ACIU Comparison
Compare WRN & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRN
- ACIU
- Stock Information
- Founded
- WRN 2006
- ACIU 2003
- Country
- WRN Canada
- ACIU Switzerland
- Employees
- WRN N/A
- ACIU N/A
- Industry
- WRN Metal Mining
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- WRN Basic Materials
- ACIU Health Care
- Exchange
- WRN Nasdaq
- ACIU Nasdaq
- Market Cap
- WRN 226.0M
- ACIU 247.4M
- IPO Year
- WRN N/A
- ACIU 2016
- Fundamental
- Price
- WRN $1.21
- ACIU $1.48
- Analyst Decision
- WRN Strong Buy
- ACIU Strong Buy
- Analyst Count
- WRN 1
- ACIU 2
- Target Price
- WRN $4.25
- ACIU $12.00
- AVG Volume (30 Days)
- WRN 381.8K
- ACIU 194.4K
- Earning Date
- WRN 05-09-2025
- ACIU 05-12-2025
- Dividend Yield
- WRN N/A
- ACIU N/A
- EPS Growth
- WRN N/A
- ACIU N/A
- EPS
- WRN N/A
- ACIU N/A
- Revenue
- WRN N/A
- ACIU $30,136,397.00
- Revenue This Year
- WRN N/A
- ACIU N/A
- Revenue Next Year
- WRN N/A
- ACIU $676.94
- P/E Ratio
- WRN N/A
- ACIU N/A
- Revenue Growth
- WRN N/A
- ACIU 84.51
- 52 Week Low
- WRN $0.90
- ACIU $1.43
- 52 Week High
- WRN $1.66
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- WRN 58.80
- ACIU 24.24
- Support Level
- WRN $0.90
- ACIU $1.48
- Resistance Level
- WRN $1.35
- ACIU $1.62
- Average True Range (ATR)
- WRN 0.08
- ACIU 0.12
- MACD
- WRN 0.02
- ACIU -0.00
- Stochastic Oscillator
- WRN 68.89
- ACIU 9.43
About WRN Western Copper and Gold Corporation
Western Copper & Gold Corp is a Canada-based exploration-stage company. The company is engaged in the exploration and development of the Casino mineral property located in Yukon, Canada (the Casino Project).
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.